Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Scott, K. Sangkuhl, Eric Gardner, C. Stein, J. Hulot, J. Hulot, Julie Johnson, D. Roden, T. Klein, A. Shuldiner, A. Shuldiner (2011)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel TherapyClinical Pharmacology & Therapeutics, 90
D. Pennell, J. Porter, A. Piga, Y. Lai, A. El‐Beshlawy, Khawla Beloul, Mohsen Elalfy, A. Yeşilipek, Y. Kilinç, T. Lawniczek, D. Habr, M. Weisskopf, Yiyun Zhang, Y. Aydinok (2012)
A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).Blood, 120
S. Yusuf, F. Zhao, S. Mehta, S. Chrolavicius, G. Tognoni, K. Fox, Clopidogrel Investigators (2001)
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.The New England journal of medicine, 345 7
D. Sibbing, Dániel Aradi, C. Jacobshagen, L. Gross, D. Trenk, T. Geisler, M. Orban, M. Hadamitzky, B. Merkely, R. Kiss, A. Komócsi, C. Dézsi, L. Holdt, S. Felix, R. Parma, M. Kłopotowski, R. Schwinger, J. Rieber, K. Huber, F. Neumann, L. Koltowski, J. Mehilli, Z. Huczek, S. Massberg, Z. Parma, M. Lesiak, Anna Komosa, M. Kowara, Bartosz Rymuza, L. Malek, Dániel Aradi, G. Veress, András Dézsi, A. Lux, J. Papp, Andrea Kovács, C. Dézsi, Sayour Amer, Z. Ruzsa, Szilárd Róna, Renáta Ili, I. Ungi, F. Nagy, R. Zweiker, G. Tóth-Gayor, P. Haller, W. Scheidt, A. Blüthgen, S. Leggewie, H. Kreider-Stempfle, T. Remp, K. Kara, A. Mügge, A. Wutzler, S. Fichtlscherer, A. Zeiher, F. Seeger, M. Hinterseer, A. König, Susanne Lederle, F. Czepluch, L. Maier, W. Schillinger, S. Sossalla, A. Hummel, S. Felix, M. Karakas, K. Sydow, T. Rudolph, M. Halbach, T. Gori, T. Münzel, A. May, Carsten-Manuel Gerstenberg, D. Pilecky, M. Deichstetter, S. Kääb, A. Löw, M. Orban, S. Sattler, Sabine Deuschl, D. Teupser, H. Mudra, Thomas Räder, T. Schütz, Felix Vahldiek, D. Divchev, H. Ince, C. Nienaber, H. Radunski, P. Boekstegers, J. Horstkotte, R. Mueller, K. Müller, R. Schwinger, Oliver Rasp (2017)
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trialThe Lancet, 390
F. Verheugt, P. Damman, S. Damen, J. Wykrzykowska, E. Woelders, R. Geuns (2021)
P2Y12 blocker monotherapy after percutaneous coronary interventionNetherlands Heart Journal, 29
Chen Guo, Min Li, Yong-Hui Lv, Ming-bo Zhang, Zhilu Wang (2020)
De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisPlatelets, 31
J. Higgins, D. Altman, P. Gøtzsche, P. Jüni, D. Moher, A. Oxman, J. Savović, K. Schulz, L. Weeks, J. Sterne (2011)
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsThe BMJ, 343
T. Cuisset, P. Deharo, J. Quilici, T. Johnson, S. Deffarges, C. Bassez, G. Bonnet, L. Fourcade, J. Mouret, M. Lambert, V. Verdier, P. Morange, M. Alessi, J. Bonnet (2017)
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized studyEuropean Heart Journal, 38
N. Pereira, C. Rihal, R. Lennon, Gil Marcus, S. Shrivastava, M. Bell, D. So, N. Geller, S. Goodman, Ahmed Hasan, A. Lerman, Y. Rosenberg, K. Bailey, M. Murad, M. Farkouh (2021)
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis.JACC. Cardiovascular interventions
M. Page, D. Moher, P. Bossuyt, I. Boutron, T. Hoffmann, C. Mulrow, Larissa Shamseer, J. Tetzlaff, E. Akl, S. Brennan, R. Chou, Julie Glanville, J. Grimshaw, A. Hrõbjartsson, M. Lalu, Tianjing Li, E. Loder, E. Mayo-Wilson, Steve McDonald, L. McGuinness, L. Stewart, James Thomas, A. Tricco, V. Welch, P. Whiting, J. McKenzie (2020)
PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviewsThe BMJ, 372
M. Sampson, K. Shojania, J. McGowan, R. Daniel, T. Rader, Alla Iansavichene, Jun Ji, M. Ansari, D. Moher (2008)
Surveillance search techniques identified the need to update systematic reviews.Journal of clinical epidemiology, 61 8
E. Amsterdam, N. Wenger, R. Brindis, D. Casey, T. Ganiats, D. Holmes, A. Jaffe, H. Jneid, R. Kelly, M. Kontos, G. Levine, P. Liebson, D. Mukherjee, E. Peterson, M. Sabatine, R. Smalling, Susan Zieman (2014)
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 64 24
M. Egger, G. Smith, Martin Schneider, C. Minder (1997)
Bias in meta-analysis detected by a simple, graphical testBMJ, 315
H. Bueno, P. Sinnaeve, L. Annemans, N. Danchin, M. Licour, J. Medina, S. Pocock, J. Sánchez-Covisa, Robert Storey, J. Jukema, U. Zeymer, F. Werf (2016)
Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patternsEuropean Heart Journal: Acute Cardiovascular Care, 5
G. Levine, E. Bates, L. Mauri, J. Bittl, R. Mehran, R. Brindis, D. Mukherjee, S. Fihn, L. Newby, L. Fleisher, P. O'Gara, C. Granger, M. Sabatine, R. Lange, Peter Smith, M. Mack, Sidney Smith, L. Curtis, S. Pressler (2016)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Journal of the American College of Cardiology, 68 10
R. Mehran, S. Rao, Deepak Bhatt, C. Gibson, A. Caixeta, J. Eikelboom, S. Kaul, S. Wiviott, V. Menon, E. Nikolsky, V. Serebruany, M. Valgimigli, P. Vranckx, D. Taggart, J. Sabik, D. Cutlip, M. Krucoff, E. Ohman, P. Steg, H. White (2011)
Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research ConsortiumCirculation, 123
M. Valgimigli, H. Bueno, R. Byrne, J. Collet, F. Costa, A. Jeppsson, P. Jüni, A. Kastrati, P. Kolh, L. Mauri, G. Montalescot, F. Neumann, M. Petricevic, M. Roffi, P. Steg, S. Windecker, J. Zamorano, G. Levine (2018)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 53 1
(2014)
Review Manager (RevMan) [computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration
E. Antman, S. Wiviott, S. Murphy, J. Voitk, Y. Hasin, P. Widimsky, H. Chandna, W. Macias, C. Mccabe, E. Braunwald (2008)
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.Journal of the American College of Cardiology, 51 21
D. Capodanno, F. Alfonso, G. Levine, M. Valgimigli, D. Angiolillo (2018)
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.Journal of the American College of Cardiology, 72 23 Pt A
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén (2009)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 361 11
Jenny Hong, R. Turgeon, G. Pearson (2019)
Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysisAnnals of Pharmacotherapy, 53
J. Dormandy, B. Charbonnel, D. Eckland, E. Erdmann, M. Massi-Benedetti, I. Moules, A. Skene, M. Tan, P. Lefèbvre, G. Murray, E. Standl, R. Wilcox, L. Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R. Heine, L. Koranyi, M. Laakso, M. Mokáň, A. Norkus, V. Pīrāgs, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Škrha, U. Smith, J. Tatoň (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 366
D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, Julia Stegherr, T. Morath, A. Schömig, N. Beckerath, A. Kastrati (2010)
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent PlacementCirculation, 121
M. Page, J. McKenzie, P. Bossuyt, I. Boutron, T. Hoffmann, C. Mulrow, Larissa Shamseer, J. Tetzlaff, E. Akl, S. Brennan, R. Chou, Julie Glanville, J. Grimshaw, A. Hrõbjartsson, M. Lalu, Tianjing Li, E. Loder, E. Mayo-Wilson, Steve McDonald, L. McGuinness, L. Stewart, James Thomas, A. Tricco, V. Welch, P. Whiting, D. Moher (2020)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsSystematic Reviews, 10
Jesse Martin, Alexis Williams, Melissa Klein, Vindhya Sriramoju, S. Madan, J. Rossi, Megan Clarke, Jonathan Cicci, L. Cavallari, K. Weck, G. Stouffer, Craig Lee (2019)
Frequency and Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy in a Real-World Clinical SettingGenetics in medicine : official journal of the American College of Medical Genetics, 22
(2011)
Cytochrome 2 C 19 * 17 Allelic Variant , Platelet Aggregation , Bleeding Events , and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
T. Ueno, H. Koiwaya, Ken-ichiro Sasaki, Y. Katsuki, Y. Katsuda, Y. Murasato, Junichiro Shimamatsu, Kyoko Umeji, Yoritaka Otsuka, T. Kawasaki, Yoshisato Shibata, Y. Fukumoto (2017)
Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stentingCardiovascular Intervention and Therapeutics, 32
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
M Valgimigli (2018)
213Eur Heart J, 39
Covidence systematic review software, Veritas Health Innovation
K. Tiroch, D. Sibbing, W. Koch, Tobias Roosen-Runge, J. Mehilli, A. Schömig, A. Kastrati (2010)
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.American heart journal, 160 3
J. Higgins, S. Thompson, J. Deeks, D. Altman (2003)
Measuring inconsistency in meta-analysesBMJ : British Medical Journal, 327
B. Kheiri, M. Osman, Ahmed Abdalla, A. Chahine, Sahar Ahmed, Khansa Osman, Ghassan Bachuwa, Mustafa Hassan, Deepak Bhatt (2018)
De-Escalation of Antiplatelet Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical TrialsJournal of Cardiovascular Pharmacology and Therapeutics, 24
R. Becker, J. Bassand, A. Budaj, D. Wojdyla, S. James, J. Cornel, J. French, C. Held, J. Horrow, S. Husted, J. López-Sendón, R. Lassila, K. Mahaffey, R. Storey, R. Harrington, L. Wallentin (2011)
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.European heart journal, 32 23
N. Pereira, R. Weinshilboum (2009)
Cardiovascular pharmacogenomics and individualized drug therapyNature Reviews Cardiology, 6
IntroductionWe aimed to evaluate the clinical benefits of a de-escalation strategy from prasugrel or ticagrelor to clopidogrel versus continuation of prasugrel or ticagrelor along with aspirin in both strategies for patients presenting with acute coronary syndrome (ACS) and treated with percutaneous coronary intervention (PCI), and to analyze the effect of the recently published randomized clinical trial (RCT) by Park et al., which included the largest sample size ever and the largest switched number of patients, on current guidelines and practices.Data SourcesThe PubMed, EMBASE, Scopus, Web of Science, Cochrane Central, and Google Scholar databases were searched systematically from inception to May 2021 by using the search terms (‘de-escalation’ OR ‘switching’) AND (‘antiplatelet’ OR ‘clopidogrel’ OR ‘ticagrelor’ OR ‘prasugrel’) AND (‘percutaneous coronary intervention’ OR ‘PCI’' OR ‘Acute coronary syndrome’ OR ‘ACS’).Study Selection and Data ExtractionWe included RCTs that reported the primary outcomes, i.e. net clinical benefits and Bleeding Academic Research Consortium (BARC) type 2 or higher bleeding. A combination of both ischemic and bleeding events was defined as a net clinical benefit.Data SynthesisA total of four RCTs were included, with 5952 patients. A random-effects meta-analysis revealed that a de-escalation strategy was associated with lower ischemic and bleeding events (net clinical benefits; risk ratio [RR] 0.63, 95% confidence interval [CI] 0.47–0.85; p = 0.003), and lower BARC type 2 or higher bleeding (RR 0.51, 95% CI 0.29–0.91; p = 0.02) when compared with a continuation strategy.Relevance to Patient Care and Clinical PracticeThe current guidelines recommend potent P2Y12 prasugrel or ticagrelor for 12 months despite their association with a high risk of bleeding. Our meta-analysis updates cardiologists, providing them with the best available evidence in managing patients with ACS who underwent PCI.ConclusionAmong patients with ACS treated with PCI, a de-escalation strategy (prasugrel or ticagrelor to clopidogrel) is associated with lower ischemic and bleeding events (net clinical benefits) and lower BARC type 2 or higher bleeding; however, due to the limited number of included studies, further high-quality studies are needed to establish the clinical efficacy of the de-escalation strategy.
American Journal of Cardiovascular Drugs – Springer Journals
Published: May 1, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.